Moumita Hazra | Pharmacology | Cancer Research Excellence Award

Published on by Medical Lab Scientist

Cancer Research Excellence Award

Moumita Hazra — Hi-Tech Medical College and Hospital · India

Moumita Hazra
Researcher Moumita Hazra
Affiliation Hi-Tech Medical College and Hospital
Country India
Scopus ID 56500363800
Documents 3
Citations 119
h-index 3
Subject Area Pharmacology
Event Medical Lab Scientist Awards
Google Scholar ZHKN3KwAAAAJ

Moumita Hazra is researcher and her profile identifies in the context of pharmacology and medically relevant clinical research. The Research record lists publications addressing pharmacovigilance, rational pharmacotherapy, medication safety and clinical treatment comparisons.  [1]

Abstract

This profile summarizes the scholarly record of Moumita Hazra, whose listed work covers clinical pharmacology, pharmacoepidemiology and pharmacovigilance. The record includes studies of haematinics, topical acne therapies, asthma medication and metformin. These subjects relate to treatment effectiveness and medication safety, although the available evidence does not independently establish a cancer-specific research portfolio or award outcome. [1]

Keywords

Moumita Hazra, Cancer Research Excellence Award, pharmacology, clinical pharmacology, pharmacovigilance, rational pharmacotherapy, pharmacoepidemiology, medication safety and clinical research.

Introduction

Clinical pharmacology evaluates the use, safety and effects of medicines in patients. Pharmacovigilance and pharmacoepidemiology contribute to monitoring adverse effects and examining treatment patterns. Hazra’s listed publications include work in these areas, offering a relevant foundation for a profile centred on medicine-related research. [1]

Research Profile

The Google Scholar document identifies pharmacology and clinical pharmacology among Hazra’s research areas. Its listed publications include articles from the International Journal of Basic and Clinical Pharmacology and other medical journals. Institutional affiliation and bibliometric figures in the infobox are details and should be checked against current authoritative profiles. [2]

Research Contributions

The available publication list covers comparative medication studies, prescribing patterns and pharmacovigilance assessments. Examples include research concerning topical acne treatments, oral haematinics, asthma rescue medication and metformin. These subjects support a cautious description of contributions to clinical pharmacotherapy; a direct connection to oncology requires additional evidence. [1]

Publications

Examples in the record include a 2019 study of pharmacoepidemiology and pharmacohaemovigilance of iron preparations, a comparative study of topical anti-acne therapies, and research comparing arformoterol with salbutamol nebulisation. The record also lists work on metformin pharmacovigilance. [1]

Research Impact

Citation counts and h-index values are indicators of scholarly visibility, but they vary by database, indexing coverage and update date. The figures should not be interpreted as proof of clinical benefit or oncology expertise. The linked Google Scholar profile provides a route for checking the displayed publication list and citation information. [2]

Award Suitability

Consideration for the Cancer Research Excellence Award should depend on documented eligibility criteria and evidence of relevant cancer research, such as oncology publications, verified contributions or translational findings. Eligibility should therefore be assessed by the event organisers using verified supporting documents. [3]

Conclusion

Moumita Hazra’s scholarly record documents research related to pharmacology, medication safety and clinical treatment evaluation. These areas are relevant to medical research, but the available source does not establish a specific cancer research achievement or confirmed award. Further verification of oncology-related work and award criteria is necessary before making a stronger recognition claim.

References

  1. Google Scholar. (n.d.). Moumita Hazra: Author profile and listed publications.
    https://scholar.google.com/citations?user=ZHKN3KwAAAAJ&hl=en
  2. Elsevier. (n.d.). Scopus author details: Moumita Hazra, Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56500363800
  3. Medical Lab Scientist Awards. (n.d.). Event website
    https://medicallabscientist.com/
  4. Hazra, M. (2022). A systematic review on metformin rational pharmacotherapeutics. International Journal of Basic & Clinical Pharmacology, 11(4), 331–335
    https://doi.org/10.18203/2319-2003.ijbcp20221600
  5. Hazra, M. (2022). An analytical quantification clinical research, and an observational descriptive qualitative pharmacological research analysis on pharmacovigilance assessments of metformin monotherapy and combination therapies: A mixed-method study
    https://doi.org/10.5455/njppp.2022.12.03128202218052022

Behnaz Bayat | Immunohaematology | Women Researcher Award

Published on by Medical Lab Scientist

Women Researcher Award

Behnaz Bayat — University of Giessen, Germany

Behnaz Bayat 
Affiliation University of Giessen
Country Germany
Scopus ID 22953143200
Documents 40
Citations 907
h-index 15
Subject Area Immunohaematology
Event Medical Lab Scientist Awards

Behnaz Bayat is a researcher. The academic recognition profile presents researcher information for Behnaz Bayat in the field of immunohaematology. The listed bibliometric indicators are attributed to the Scopus profile and should be checked against the current database record before publication.[1]

Abstract

The Women Researcher Award profile documents the academic affiliation and bibliometric indicators of Behnaz Bayat. Her stated subject area is immunohaematology, a discipline concerned with interactions between blood components and immune mechanisms. This page provides a structured overview for recognition-related information and independent verification.

Keywords

Behnaz Bayat, Women Researcher Award, immunohaematology, bibliometrics, Scopus, research recognition, Medical Lab Scientist Awards.

Introduction

Academic recognition can help communicate research activity and professional contributions. Responsible researcher profiles distinguish verifiable database information from interpretations, nominations, and award decisions. The information presented here is descriptive and does not independently establish award selection or endorsement.

Research Profile

The Research profile lists 40 documents, 907 citations, and an h-index of 15. These figures may change as publications are indexed and citation records are updated. Scopus author profiles can be consulted to verify author identity and associated publication metrics.[1]

Research Contributions

Immunohaematology encompasses the study of immune processes involving blood cells, antigens, and antibodies, including topics relevant to transfusion practice and laboratory investigation. Specific contributions by the researcher should be described using verified publications rather than inferred from subject classification alone.[2]

Publications

Behnaz Bayat has contributed to scientific research in immunohaematology, including studies on platelet immunology, blood group antigens, and transfusion-related immune responses. Her co-authored publications address antibody characterization, platelet interactions, and mechanisms associated with transfusion complications. These research contributions can be explored through the linked DOI records.

Research Impact

Citation counts and the h-index provide quantitative views of scholarly attention, but they do not independently measure research quality, clinical value, or societal benefit. Comparisons should consider disciplinary practices, career stage, database coverage, and publication type.[3]

Award Suitability

The profile is formatted for consideration in connection with the Women Researcher Award associated with Medical Lab Scientist Awards. Eligibility and selection should be assessed using the organizer’s published criteria, supporting evidence, and applicable review process. This profile alone does not confirm nomination, eligibility, or receipt of an award.

Conclusion

This page consolidates the professional and bibliometric details in a consistent academic format. Before publication, confirm the institutional affiliation, current metrics, researcher identity, and any award-related statements against reliable records. An ORCID identifier and verified publication references can be added when available.

References

    1. Elsevier. (n.d.). Scopus author details: Behnaz Bayat, Author ID 22953143200. Scopus.
      https://www.scopus.com/authid/detail.uri?authorId=22953143200
    2. Traum, A., Hofmann, C., Haas, S., Schmidt, S., Bein, G., Sachs, U. J., & Bayat, B. (2021). Characterization of CD177-reactive iso- and auto-antibodies. Transfusion.
      https://doi.org/10.1111/trf.16359
    3. Bayat, B., Nielsen, K. R., Bein, G., Traum, A., Burg-Roderfeld, M., & Sachs, U. J. (2021). Transfusion of Target Antigens to Pre-Immunized Recipients: A New Mechanism in Transfusion-Related Acute Lung Injury. Blood Advances, 5(20), 3975–3985.  https://doi.org/10.1182/bloodadvances.2020003843
    4. Santoso, S., Wihadmadyatami, H., Bakchoul, T., Werth, S., Al-Fakhri, N., Bein, G., Kiefel, V., Zhu, J., Bayat, B., et al. (2016). Antiendothelial αvβ3 Antibodies Are a Major Cause of Intracranial Bleeding in Fetal/Neonatal Alloimmune Thrombocytopenia. Arteriosclerosis, Thrombosis, and Vascular Biology.
      https://doi.org/10.1161/ATVBAHA.116.307281
    5. Korkmaz, B., Kuhl, A., Bayat, B., Santoso, S., Jenne, D. E., et al. (2009). A Hydrophobic Patch on Proteinase 3, the Target of Autoantibodies in Wegener Granulomatosis, Mediates Membrane Binding via NB1 Receptors. Journal of Biological Chemistry.  https://doi.org/10.1074/JBC.M806754200

Yong-Le Yang | Virology | Innovative Research Award

Published on by Medical Lab Scientist

Innovative Research Award

Yong-Le Yang — Xianghu Laboratory, China

Yong-Le Yang
Affiliation Xianghu Laboratory
Country China
Scopus ID 57195945518
Documents 38
Citations 1,194
h-index 16
Subject Area Virology
Event Name Medical Lab Scientist Awards
ORCID 0000-0002-3266-8019

Yong-Le Yang is a researcher, whose ORCID record identifies virology as a research keyword and lists publications concerning animal coronaviruses, viral infection, molecular diagnostics and host-pathogen interactions. This article presents his research profile and selected publications in the context of the Innovative Research Award. [1]

Abstract

Yong-Le Yang’s research focuses on virology, with particular emphasis on animal coronaviruses, viral infection mechanisms, host–pathogen interactions, and molecular diagnostic approaches. His published studies investigate aspects of swine enteric coronavirus biology, including viral entry, protein function, and the development of laboratory detection methods. [1]

Keywords

Virology, animal coronaviruses, viral pathogenesis, molecular diagnostics, host-pathogen interactions, swine enteric viruses, research publications, citation analysis and scientific recognition.

Introduction

Virology examines viral structure, replication, transmission and interactions with host organisms. Research into animal coronaviruses contributes to understanding infection mechanisms and developing diagnostic approaches. Yang’s publications address several of these subjects, providing context for evaluating his research activities and scientific contributions. [2]

Research Profile

The profile reports 38 documents, 1,194 citations and an h-index of 16. These metrics provide quantitative information about publication and citation records, although values may change across databases and over time. His ORCID record lists Xianghu Laboratory and identifies virology among his research keywords. [1]

Research Contributions

Yang’s documented publications include research on swine acute diarrhea syndrome coronavirus, porcine deltacoronavirus, viral entry and molecular detection. These studies investigate mechanisms associated with infection and approaches to laboratory diagnosis. Together, the publications represent research activity across experimental virology and applied diagnostic investigation. [3]

Publications

Selected publications include a 2022 study of bile-acid-associated coronavirus entry in porcine intestinal enteroids, a 2022 article on multiplex real-time RT-PCR for swine enteric coronaviruses, and a 2020 review of swine enteric alphacoronavirus. These research topics contribute to the scientific understanding of emerging animal viruses and provide relevant evidence for further investigation into viral pathogenesis and diagnostic development. [4]

Research Impact

Citation counts and the h-index provide indicators of scholarly visibility but do not independently establish research quality or practical impact. Their interpretation should consider subject-specific citation patterns, publication dates, authorship contributions and the significance of individual findings. Verification against the relevant databases is recommended before formal assessment. [5]

Award Suitability

Yang’s documented research topics and bibliometric indicators may be considered when reviewing his suitability for the Innovative Research Award. A balanced evaluation should verify publication attribution, assess research originality and significance, and apply transparent eligibility criteria. This profile does not represent confirmation of award selection.

Conclusion

Yong-Le Yang’s research profile reflects activity in virology, particularly animal coronavirus research and diagnostic methods. His publication record and bibliometric indicators provide useful background for scholarly review. Any recognition decision should be based on verified evidence and consistent evaluation criteria.

References

  1. ORCID. Yongle Yang researcher record.
    https://orcid.org/0000-0002-3266-8019
  2. Yang, Y.-L., et al. (2022). Bile acids promote the caveolae-associated entry of swine acute diarrhea syndrome coronavirus in porcine intestinal enteroids. PLOS Pathogens.
    https://doi.org/10.1371/journal.ppat.1010620 
  3. Zhu, J.-H., et al. (2022). Development and Clinical Applications of a 5-Plex Real-Time RT-PCR for Swine Enteric Coronaviruses. Viruses.
    https://doi.org/10.3390/v14071536
  4. Yang, Y.-L., Yu, J.-Q., and Huang, Y.-W. (2020). Swine enteric alphacoronavirus: An update three years after its discovery. Virus Research.
    https://doi.org/10.1016/j.virusres.2020.198024
  5. Elsevier. Scopus author details: Yong-Le Yang, Author ID 57195945518.
    https://www.scopus.com/authid/detail.uri?authorId=57195945518

 

David Stejskal | Clinical Chemistry | Innovative Biomedical Research Award

Published on by Medical Lab Scientist

Innovative Biomedical Research Award

David Stejskal
Affiliation Institute of Laboratory Medicine, University Hospital and Faculty of Medicine, Ostrava University
Country Czech Republic
Scopus ID 7005865420
Documents 213
Citations 3,995
h-index 30
Subject Area Clinical Chemistry
Event Medical Lab Scientist Awards
ORCID 0000-0003-1204-0395

David Stejskal is a Czech researcher and laboratory medicine specialist associated with the Institute of Laboratory Medicine at University Hospital Ostrava and the Faculty of Medicine of the University of Ostrava. His scholarly activity is situated principally within clinical chemistry, laboratory diagnostics, biomarker research and related biomedical disciplines.[1]

Abstract

This academic recognition profile summarizes the documented research activity of David Stejskal in clinical chemistry, laboratory medicine and biomedical research. His publication record encompasses diagnostic biomarkers, analytical and pre-analytical laboratory problems, cardiovascular biomarker research, neurodegenerative disease biomarkers and quantitative laboratory methodology.[1]

Keywords

Clinical chemistry, laboratory medicine, biomedical research, diagnostic biomarkers, clinical biochemistry, laboratory diagnostics, microRNAs, cardiovascular biomarkers, neurodegenerative disease biomarkers, analytical chemistry, chromatography, mass spectrometry, potassium measurement, laboratory interference, translational diagnostics, University Hospital Ostrava.[2]

Introduction

Clinical chemistry provides quantitative laboratory information that supports disease detection, differential diagnosis, monitoring and clinical decision-making. Contemporary laboratory medicine increasingly combines conventional biochemical testing with molecular biomarkers, advanced analytical technologies and rigorous assessment of factors that can influence laboratory results.[2]

Research Profile

David Stejskal is affiliated with the Institute of Laboratory Medicine in Ostrava, Czech Republic, with published research identifying connections to University Hospital Ostrava and the Faculty of Medicine at the University of Ostrava. His ORCID identifier, 0000-0003-1204-0395, provides a persistent scholarly identifier for author attribution and research discovery.[3]

Research Contributions

One component of Stejskal’s work concerns clinically important laboratory measurement and interpretation. A 2024 report on pseudonormokalemia examined circumstances in which serum potassium can appear to remain within a reference interval despite a substantially different plasma potassium concentration, particularly in the setting of thrombocytosis.[3]

Publications

David Stejskal’s research portfolio demonstrates broad contributions to laboratory medicine, clinical biochemistry, molecular biomarkers, and diagnostic research. His publications address important topics including pseudonormokalemia and potassium measurement, circulating microRNAs in heart failure, advanced mass-spectrometric quantification of insulin and insulin analogues, urinary fetuin-A in urolithiasis, and urinary N1,N12-diacetylspermine as a potential bladder-cancer marker.[4]

Research Impact

The supplied Scopus indicators report 213 indexed documents, 3,995 citations and an h-index of 30 for David Stejskal. In bibliometric terms, document count reflects indexed scholarly output, total citations indicate how frequently indexed publications have been cited by subsequent literature, and the h-index combines aspects of publication productivity and citation distribution.[4]

Award Suitability

For consideration under the Innovative Biomedical Research Award within the Medical Lab Scientist Awards, Stejskal’s documented profile presents several characteristics relevant to an academic evaluation. These include a substantial indexed publication record, sustained citation activity, research within clinical chemistry and laboratory medicine, participation in biomarker-oriented investigations and contributions to analytical and diagnostic methodology.[5]

Conclusion

David Stejskal’s academic profile reflects sustained activity in clinical chemistry, laboratory medicine and biomedical research. His documented work encompasses clinically relevant laboratory interpretation, molecular and biochemical biomarkers, neurodegenerative and cardiovascular research and advanced analytical methodology.[5]

References

  1. Elsevier. (n.d.). Scopus author details: David Stejskal, Author ID 7005865420. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=7005865420
  2. ORCID. (n.d.). ORCID record: David Stejskal, 0000-0003-1204-0395. ORCID.
    https://orcid.org/0000-0003-1204-0395
  3. Medical Lab Scientist Awards. (n.d.). Medical Lab Scientist Awards academic and scientific recognition platform.
    https://medicallabscientist.com/
  4. Chobolová, N., Švagera, Z., Stejskal, D., & Bužga, M. (2026). Candidate circulating microRNAs in patients with sarcopenic obesity: Results of a pilot screening. Biomedicines, 14(6), 1377.
    https://doi.org/10.3390/biomedicines14061377
  5. Zhang, X., Yeung, D. C. Y., Karpisek, M., Stejskal, D., Zhou, Z.-G., Liu, F., Wong, R. L. C., Chow, W.-S., Tso, A. W. K., Lam, K. S. L., & Xu, A. (2008). Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes, 57(5), 1246–1253.
    https://doi.org/10.2337/db07-1476

Xiao Dong | Cancer | Innovative Research Award

Published on by Medical Lab Scientist

Innovative Research Award

Xiao Dong
Affiliation Shanghai University
Country China
Scopus ID 56457039700
Documents 30
Citations 1,898
h-index 17
Subject Area Cancer
Event Medical Lab Scientist Awards
ORCID 0000-0001-6897-6999

Xiao Dong is a researcher associated with Shanghai University whose academic work includes cancer-related biomaterials, nanomedicine, tumor-responsive therapeutic systems, and cancer immunotherapy. His scholarly profile identifies research activity at the interface of biomedical materials, drug-delivery technology, tumor biology, and therapeutic innovation.[1]

Abstract

This academic recognition profile summarizes the research record of Xiao Dong in the broad subject area of cancer, with particular emphasis on biomedical materials, nanomedicine, tumor-responsive therapeutic platforms, and cancer immunotherapy. Recent published research associated with Dong includes the development of a hypochlorous acid-responsive prodrug nanoplatform designed to integrate tumor-responsive drug activation with immunotherapeutic mechanisms[1]

Keywords

Cancer, cancer immunotherapy, nanomedicine, biomaterials, tumor microenvironment, drug delivery, prodrug nanoplatform, tumor-responsive therapy, STING agonist, biomedical engineering, anticancer therapeutics, immune response, translational research, Shanghai University, medical research, therapeutic innovation.[2]

Introduction

Cancer research increasingly integrates molecular biology, immunology, materials science, pharmacology, and bioengineering to address challenges associated with treatment resistance, tumor heterogeneity, systemic toxicity, and the immunosuppressive tumor microenvironment. Nanomedicine represents one interdisciplinary approach in which engineered materials are investigated as carriers or responsive platforms for delivering therapeutic agents to tumors.[2]

Research Profile

Xiao Dong is associated with Shanghai University in China. Published work identifies affiliations that include Shanghai 411 Hospital/Shanghai University and the Institute of Artificial Intelligence and Biomanufacturing within the School of Medicine at Shanghai University. His ORCID identifier is 0000-0001-6897-6999, providing a persistent identifier for attribution and discovery of scholarly activity. [3]

Research Contributions

A notable component of Xiao Dong’s research concerns the application of engineered nanomedicine systems to cancer therapy. In a 2026 study published in Biomaterials Research, Dong and collaborators reported a hypochlorous acid-responsive prodrug nanoplatform for synergistic cancer immunotherapy. The experimental system combined a stimulus-responsive methylene blue–doxorubicin dimer prodrug with a stimulator of interferon genes agonist, with the objective of coordinating tumor-responsive therapeutic activity and antitumor immune stimulation. [3]

Publications

Hypochlorous Acid-Responsive Prodrug Nanoplatform for Synergistic Cancer Immunotherapy. Published in Biomaterials Research in 2026, this investigated a responsive prodrug nanoplatform combining chemotherapy-related mechanisms with immune activation for experimental cancer treatment.Tumor Metabolism-Rewriting Nanomedicines for Cancer Immunotherapy. [4]

Research Impact

The supplied Scopus indicators report 30 indexed documents, 1,898 citations, and an h-index of 17 for Xiao Dong. These figures indicate that a portion of the researcher’s indexed scholarly output has received citation attention from subsequent academic literature. The h-index represents a combined measure of publication productivity and citation distribution, while the total citation count describes citation reception across indexed documents. [4]

Award Suitability

For consideration under an Innovative Research Award in the subject area of cancer, Xiao Dong’s documented research record presents several academically relevant characteristics. These include participation in multidisciplinary cancer research, development and evaluation of tumor-responsive therapeutic platforms, integration of nanomedicine with immunotherapeutic mechanisms, and contribution to research examining biological barriers within the tumor microenvironment. [5]

Conclusion

Xiao Dong’s research profile reflects interdisciplinary work in cancer-related biomaterials, nanomedicine, tumor-responsive therapeutic systems, and cancer immunotherapy. Published research demonstrates engagement with strategies designed to combine targeted or stimulus-responsive drug activity with modulation of antitumor immunity.[5]

References

  1. Elsevier. (n.d.). Scopus author details: Xiao Dong, Author ID 56457039700. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56457039700
  2. ORCID. (n.d.). ORCID record: Xiao Dong, 0000-0001-6897-6999. ORCID.
    https://orcid.org/0000-0001-6897-6999
  3. Medical Lab Scientist Awards. (n.d.). Medical Lab Scientist Awards academic and scientific recognition platform.
    https://medicallabscientist.com/
  4. Xia, S., Wang, X., Liu, C., Ji, R., Wang, M., Zhang, C., Chen, L., Chen, W., Yao, S. Q., Fang, C., & Dong, X. (2026). Hypochlorous Acid-Responsive Prodrug Nanoplatform for Synergistic Cancer Immunotherapy. Biomaterials Research, 30, Article 0300.
    https://doi.org/10.34133/bmr.0300
  5. Wang, X., Liu, C., Ji, R., Liu, J., Shao, Y., Xia, S., Li, J., Zhang, X., Luo, L., Wu, Y., Yao, S. Q., Fang, C., Chen, L., & Dong, X. (2026). Lipid droplet-targeted biomimetic liposomes potentiate chemo-ferroptosis therapy in leukemia. Advanced Materials.
    https://doi.org/10.1002/adma.202515716

Romaric Tuono De Manfouo | Hemostasis | Innovative Research Award

Published on by Medical Lab Scientist

Innovative Research Award

Romaric Tuono De Manfouo
Affiliation Université des Montagnes
Country Cameroon
Scopus ID 57739398300
Documents 13
Citations 21
h-index 3
Subject Area Hemostasis
Event Medical Lab Scientist Awards
ORCID 0000-0002-2867-0538

Romaric Tuono De Manfouo is a Cameroon-based biomedical researcher affiliated with Université des Montagnes whose published work spans hematology, hemostasis, sickle cell disease, thrombosis-related biomarkers, anemia, iron metabolism, inflammation, and related clinical laboratory investigations. [1]

Abstract

This academic recognition profile summarizes the scholarly record of Romaric Tuono De Manfouo within hemostasis, hematology, and related biomedical sciences. His published work has examined hematological and hemostatic abnormalities in sickle cell disease, biomarkers associated with thrombotic risk, iron metabolism, inflammation, haptoglobin biology, anemia, and blood-donor health. [1]

Keywords

Hemostasis, hematology, thrombosis, thrombotic risk, plasminogen, sickle cell disease, coagulation, anemia, iron deficiency, inflammation, haptoglobin, hematological profile, laboratory medicine, blood disorders, clinical biomarkers, Cameroon, medical laboratory science. [2]

Introduction

Hemostasis is the coordinated physiological process through which vascular integrity is maintained while excessive bleeding and inappropriate thrombosis are prevented. Research in this field frequently integrates platelet biology, coagulation pathways, fibrinolysis, hematological parameters, inflammatory mechanisms, and clinical risk assessment.[2]

Research Profile

Romaric Tuono De Manfouo is affiliated with Université des Montagnes in Bangangté, Cameroon. Published articles have also identified research affiliations with the Faculty of Medicine and Biomedical Sciences of Université de Yaoundé I. His ORCID identifier, 0000-0002-2867-0538, provides a persistent scholarly identifier associated with his research output. [3]

Research Contributions

A major contribution of De Manfouo’s work is the study of thrombosis-related and hemostatic abnormalities in sickle cell disease. In a study examining hematological and hemostatic profiles in Cameroonian patients with sickle cell disease, the research focused on laboratory characteristics associated with thrombotic risk.[3]

Publications

Romaric Tuono De Manfouo’s research portfolio reflects a sustained focus on hemostasis, hematology, thrombosis, inflammation, and related clinical laboratory investigations. His publications include studies examining plasminogen as a potential marker of thrombotic risk in patients with hepatitis, hematological and hemostatic profiles associated with thrombosis in sickle cell disease, and iron status and inflammation in sickle cell populations.[4]

Research Impact

The supplied Scopus metrics indicate 13 indexed documents, 21 citations, and an h-index of 3. These indicators provide a quantitative view of publication activity and citation reception within the Scopus database, although they should not be interpreted independently of publication quality, study design, authorship contribution, disciplinary citation practices, and the clinical relevance of the underlying research. [4]

Award Suitability

For consideration under an Innovative Research Award in the subject area of hemostasis, De Manfouo’s documented research record demonstrates several academically relevant characteristics. These include investigation of thrombotic risk in sickle cell disease, evaluation of fibrinolytic biomarkers such as plasminogen, integration of hematological and inflammatory measurements.[5]

Conclusion

Romaric Tuono De Manfouo’s research profile is characterized by work at the intersection of hematology, hemostasis, inflammation, and clinical laboratory science. His studies on thrombotic risk in sickle cell disease, plasminogen during hepatitis, iron status, oxidative stress, haptoglobin, anemia, and blood-donor health demonstrate a sustained interest in laboratory-based assessment of hematological disorders and clinically relevant biomarkers. [5]

References

  1. Elsevier. (n.d.). Scopus author details: Romaric Tuono De Manfouo, Author ID 57739398300. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57739398300
  2. ORCID. (n.d.). ORCID record: Romaric Tuono De Manfouo, 0000-0002-2867-0538. ORCID.
    https://orcid.org/0000-0002-2867-0538
  3. Medical Lab Scientist Awards. (n.d.). Medical Lab Scientist Awards academic and scientific recognition platform.
    https://medicallabscientist.com/
  4. Tuono, R. D. M., Tchoumke, M. M., Tepe, W. A. D., Jeuta, W. K., Fewou, S. N., et al. (2025). Plasminogen as a Marker for Assessing Thrombotic Risk During Hepatitis in Cameroon: Case-Control Study. Health Science Reports.
    https://doi.org/10.1002/hsr2.70648
  5. Simo, J. L., Angandji, P. T., Tuono, R. D. M., Njinjou, K. F., Yong, I. W. S., Njopwouo, M. S., & Chuisseu, P. D. D. (2026). Hepatic enzyme abnormalities and their association with hematological parameters in sickle cell disease A case-control study in Cameroon. Health Science Reports.
    https://doi.org/10.1002/hsr2.72649

 

Lingkai Zhang | Oncology | Innovative Research Award

Published on by Medical Lab Scientist

Innovative Research Award

Lingkai Zhang
Affiliation Fudan University
Country China
Scopus ID 59507405200
Documents 8
Citations 9
h-index 2
Subject Area Oncology
Event Medical Lab Scientist Awards
ORCID 0009-0001-0405-057X

Lingkai Zhang is a researcher affiliated with Fudan University in Shanghai, China, whose scholarly activity is associated with oncology and particularly with research into urothelial carcinoma, tumor biology, immune-cell infiltration, molecular biomarkers, and the tumor immune microenvironment. [1]

Abstract

This academic recognition profile summarizes the research record of Lingkai Zhang of Fudan University within the subject area of oncology. His published work includes investigations of urothelial carcinoma with emphasis on the tumor immune microenvironment, immune-cell infiltration, clinically relevant molecular alterations, proliferative tumor characteristics, and factors associated with patient prognosis or therapeutic response. [1]

Keywords

Oncology, urothelial carcinoma, tumor immunology, tumor immune microenvironment, natural killer cells, CD8+ T cells, ARID1A, molecular biomarkers, cancer prognosis, immunotherapy, tumor proliferation, precision oncology, immune infiltration, cancer biology, translational research. [2]

Introduction

Modern oncology increasingly integrates tumor genomics, immunology, pathology, and clinical outcome data to understand biological heterogeneity and identify variables that may influence disease progression or treatment response. Urothelial carcinoma represents an important setting for such investigations because tumor behavior may be shaped by molecular alterations together with interactions between malignant cells and immune populations in the surrounding microenvironment.[2]

Research Profile

Lingkai Zhang is affiliated with Fudan University in Shanghai, China. Published articles identify an affiliation with the National Health Commission Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University. His ORCID record is identified by 0009-0001-0405-057X, providing a persistent digital identifier for scholarly attribution. [3]

Research Contributions

A principal theme within Zhang’s documented research is the investigation of immune and molecular heterogeneity in urothelial carcinoma. One study examined natural killer cell infiltration and its relationship with sex-dependent clinical outcomes, addressing how immune-cell abundance may have distinct clinical associations across patient groups.[3]

Publications

Lingkai Zhang is a researcher affiliated with Fudan University, China, whose work focuses on oncology, particularly urothelial carcinoma and tumor immunology. His research examines the relationships between immune-cell infiltration, molecular alterations, tumor biology, prognosis, and therapeutic response.His publications include studies on natural killer cell infiltration, ARID1A loss and CD8+ T-cell infiltration, proliferative ecotypes, and TERT promoter alterations in urothelial carcinoma.[4]

Research Impact

The supplied Scopus information reports 8 indexed documents, 9 citations, and an h-index of 2 for Lingkai Zhang. These values describe the research record within the Scopus indexing environment at the time the metrics were supplied. Citation totals and h-index values are dynamic indicators and can change as publications accumulate citations and bibliographic databases update their records. [4]

Award Suitability

For consideration within an Innovative Research Award framework in oncology, Zhang’s research record contains several elements relevant to an innovation-focused academic assessment. These include investigation of the tumor immune microenvironment, integration of molecular alterations with immune-cell characteristics, evaluation of clinically relevant patient cohorts, and exploration of biological classifications associated with prognosis or therapeutic benefit. [5]

Conclusion

Lingkai Zhang’s academic profile at Fudan University is associated with oncology research focused substantially on urothelial carcinoma and its molecular and immunological heterogeneity. His published studies include investigations of natural killer cell infiltration, CD8+ T-cell activity, ARID1A-related tumor characteristics, TERT-associated disease features, and proliferation-based tumor ecotypes. [5]

References

  1. Elsevier. (n.d.). Scopus author details: Lingkai Zhang, Author ID 59507405200. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=59507405200
  2. ORCID. (n.d.). ORCID record: Lingkai Zhang, 0009-0001-0405-057X. ORCID.
    https://orcid.org/0009-0001-0405-057X
  3. Medical Lab Scientist Awards. (n.d.). Academic and scientific recognition platform.
    https://medicallabscientist.com/
  4. Liu, Z., Zhang, L., Jin, K., et al. (2025). ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma. Clinical Cancer Research, 31(20), 4311–4322.
    https://doi.org/10.1158/1078-0432.CCR-25-0816
  5. Zhang, L., Liu, Z., Ding, Y., Sun, J., Wu, Y., Su, X., Jin, K., et al. (2025). Natural killer cell infiltration elicits gender-dependent dichotomous clinical outcomes in urothelial carcinoma. Cancer, 131(24), e70196.
    https://doi.org/10.1002/cncr.70196

Seyed-Alireza Esmaeili | Microbiota | Innovative Research Award

Published on by Medical Lab Scientist

Innovative Research Award

Seyed-Alireza Esmaeili
Affiliation Immunology Department, Mashhad University of Medical Sciences, Mashhad, Iran
Country Iran
Scopus ID 57188748201
Documents 106
Citations 7,446
h-index 31
Subject Area Microbiota
Event Medical Lab Scientist Awards
ORCID 0000-0002-9371-4170

Assoc. Prof. Dr Seyed-Alireza Esmaeili is a researcher affiliated with the Immunology Department of Mashhad University of Medical Sciences in Iran. His indexed scholarly profile is associated with microbiota, probiotics, immunology, immune regulation, and autoimmune disease research. The research profile also includes an ORCID identifier that supports persistent attribution of scholarly work. [1]

Abstract

This academic recognition profile presents the research record of Seyed-Alireza Esmaeili, affiliated with Mashhad University of Medical Sciences in Iran. His research profile is associated with microbiota and immunology, with scholarly work addressing probiotics, immune regulation, autoimmune disorders, inflammatory mechanisms, and interactions between microbial systems and host immunity. [1]

Keywords

Microbiota, probiotics, immunology, immune regulation, autoimmune disease, systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, dendritic cells, macrophages, T cells, gut microbiome, oral microbiota, tolerogenic probiotics, inflammatory disease, translational immunology, biomedical research. [2]

Introduction

Microbiota research examines the relationships between microbial communities and their hosts and has become increasingly relevant to immunology, metabolic science, inflammatory disease, and translational medicine. Research into probiotics is one component of this broader field, particularly where microorganisms or microbial products are investigated for possible effects on immune signaling and physiological homeostasis. [2]

Research Profile

Seyed-Alireza Esmaeili is affiliated with the Immunology Department of Mashhad University of Medical Sciences, Mashhad, Iran. The supplied Scopus author information identifies the researcher through Author ID 57188748201 and reports 106 documents, 7,446 citations, and an h-index of 31. [3]

Research Contributions

A significant research theme is the study of tolerogenic probiotics as potential immunomodulatory agents. Research in this area has considered how probiotic organisms may influence immune tolerance and inflammatory pathways, particularly in autoimmune disorders. Work on systemic lupus erythematosus has examined potential relationships between probiotic interventions and immune-cell function. [3]

Publications

Seyed-Alireza Esmaeili’s research record comprises 106 documents, with a strong focus on microbiota, probiotics, immunology, and immune-mediated diseases. His selected publications investigate the immunoregulatory potential of tolerogenic probiotics in systemic lupus erythematosus, allergy, psoriatic arthritis, and rheumatoid arthritis, including their effects on dendritic cells, macrophages, T-cell subsets, and inflammatory responses. [4]

Research Impact

The supplied Scopus profile reports 7,446 citations and an h-index of 31 for Seyed-Alireza Esmaeili. These indicators provide quantitative measures of scholarly visibility within the relevant indexing system. Citation counts and h-index values are database-dependent and can change over time as new publications and citations are indexed. [4]

Award Suitability

The Innovative Research Award profile is presented in the subject area of microbiota. Esmaeili’s research record contains several characteristics relevant to an innovation-focused academic assessment, including sustained investigation of probiotic–immune interactions, research into tolerogenic mechanisms, application of microbiota concepts to autoimmune disease, and continued investigation of emerging host–microbiota relationships. [5]

Conclusion

Seyed-Alireza Esmaeili’s research profile is associated with microbiota, probiotics, immunology, and autoimmune disease research at Mashhad University of Medical Sciences. His scholarly work addresses microbial influences on immune regulation through research involving probiotics, dendritic cells, macrophages, T-cell responses, and microbiota-associated disease mechanisms. [5]

References

  1. Elsevier. (n.d.). Scopus author details: Seyed-Alireza Esmaeili, Author ID 57188748201. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57188748201
  2. ORCID. (n.d.). ORCID record: Seyed-Alireza Esmaeili. ORCID.
    https://orcid.org/0000-0002-9371-4170
  3. World Research Awards. (n.d.). Medical Lab Scientist Awards.
    https://medicallabscientist.com/
  4. Ahmadi-Khorram, M., Mahmoudi, M., Kheder, R. K., Rastin, M., Hatami, A., Fadaee, A., & Esmaeili, S.-A. (2025). Induction of lupus T cell subset by probiotics-matured tolerogenic dendritic cells. Food Science & Nutrition, 13(12), e71283.
    https://doi.org/10.1002/fsn3.71283
  5. Javanmardi, Z., Mahmoudi, M., Rafatpanah, H., Rezaieyazdi, Z., Shapouri-Moghaddam, A., Ahmadi, P., Mollazadeh, S., Tabasi, N. S., & Esmaeili, S.-A. (2024). Tolerogenic probiotics Lactobacillus delbrueckii and Lactobacillus rhamnosus promote anti-inflammatory profile of macrophages-derived monocytes of newly diagnosed patients with systemic lupus erythematosus. Cell Biochemistry and Function, 42(2),
    https://doi.org/10.1002/cbf.3981

Ana Claudia Oliveira Carreira | Angiogenesis | Excellence in Research Award

Published on by Medical Lab Scientist

Excellence in Research Award

Ana Claudia Oliveira Carreira
Affiliation Federal University of ABC
Country Brazil
Scopus ID 57064088000
Documents 80
Citations 2,166
h-index 22
Subject Area Angiogenesis
Event Medical Lab Scientist Awards
ORCID 0000-0002-9142-1155
Google Scholar ID E_4m1ZEAAAAJ&hl=pt-BR

Ana Claudia Oliveira Carreira is a researcher affiliated with the Federal University of ABC in Brazil, with a research profile associated with angiogenesis. The supplied Scopus information records 80 documents, 2,166 citations, and an h-index of 22.[1]

Abstract

Ana Claudia Oliveira Carreira is affiliated with the Federal University of ABC in Brazil and is identified in the supplied research information with the subject area of angiogenesis. Her Scopus profile records 80 documents, 2,166 citations, and an h-index of 22. These bibliometric indicators provide a structured overview of her documented research output and citation record.[1]

Keywords

Ana Claudia Oliveira Carreira is a researcher affiliated with the Federal University of ABC whose academic work is associated with angiogenesis and biomedical research. Her research profile is documented through Scopus, providing bibliometric information relevant to research impact and scholarly visibility.[2]

Introduction

Angiogenesis refers to the formation of new blood vessels from existing vasculature and represents an important area of biomedical research because vascular development and remodeling are relevant to physiological and pathological processes. Within this broad research context, the supplied profile identifies Ana Claudia Oliveira Carreira with angiogenesis as her subject area and documents a substantial body of indexed scholarly output. [2]

Research Profile

The supplied Scopus record identifies Ana Claudia Oliveira Carreira through Author ID 57064088000 and associates the profile with 80 documents, 2,166 citations, and an h-index of 22. The affiliation listed for the researcher is the Federal University of ABC, Brazil, while angiogenesis is provided as the principal subject area for this recognition profile. [3]

Research Contributions

Based on the supplied profile information, Carreira’s documented research contribution is represented by a body of 80 Scopus-indexed documents within a profile associated with angiogenesis. The citation record of 2,166 citations indicates that the indexed publications have accumulated citations within the Scopus database.[3]

Publications

The supplied information records 80 documents for Ana Claudia Oliveira Carreira in Scopus. The available source data in this profile does not provide a complete publication-by-publication bibliography, individual article titles, publication dates, journal details, or verified DOI identifiers. Accordingly, specific publications are not listed here beyond the documented aggregate publication count. [4]

Research Impact

The supplied bibliometric record reports 2,166 citations across 80 documents and an h-index of 22. These indicators provide quantitative information about the visibility and citation history of the indexed research record. They do not, by themselves, establish the societal, clinical, translational, or qualitative significance of individual studies. [4]

Award Suitability

For the purposes of the Excellence in Research Award profile presented here, the documented research record includes an affiliation with the Federal University of ABC, an identified subject area of angiogenesis, 80 Scopus documents, 2,166 citations, and an h-index of 22. These details provide documented bibliometric and affiliation information relevant to an academic recognition profile. [5]

Conclusion

Ana Claudia Oliveira Carreira’s supplied research profile documents an affiliation with the Federal University of ABC in Brazil and an academic focus associated with angiogenesis. The reported Scopus record comprises 80 documents, 2,166 citations, and an h-index of 22. Together with the ORCID and supplied Google Scholar identifiers, these records provide a structured basis for identifying and documenting the research profile. [5]

References

  1. Elsevier. (n.d.). Scopus author details: Ana Claudia Oliveira Carreira, Author ID 57064088000. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57064088000
  2. ORCID. (n.d.). Ana Claudia Oliveira Carreira: ORCID record 0000-0002-9142-1155. ORCID.
    https://orcid.org/0000-0002-9142-1155
  3. Google Scholar. (n.d.). Researcher profile identifier supplied for Ana Claudia Oliveira Carreira: E_4m1ZEAAAAJ&hl=pt-BR. Google Scholar.
    https://scholar.google.com/citations?user=E_4m1ZEAAAAJ&hl=pt-BR
  4. Fernandes, L. A., Magalhães, G. R. I., & Carreira, A. C. O. (2025). Assays of angiogenic potential using quail and chicken chorioallantoic membrane (CAM). Current Protocols.
    https://doi.org/10.1002/cpz1.70223
  5. Almeida, G. H. D. R., Gibin, M. S., … Carreira, A. C. O. (2024). Development and biocompatibility assessment of decellularized porcine uterine extracellular matrix-derived grafts. Tissue Engineering Part C: Methods, 30(12).
    https://doi.org/10.1089/ten.tec.2024.0229

Miguel Relloso | Reproduction Immunology | Innovative Research Award

Published on by Medical Lab Scientist

Innovative Research Award

Miguel Relloso
Affiliation Instituto de Investigación Sanitaria Gregorio Marañón
Country Spain
Scopus ID 6602575402
Documents 34
Citations 1,417
h-index 21
Subject Area Reproduction Immunology
Event Medical Lab Scientist Awards
ORCID 0000-0002-9181-2244

Miguel Relloso is a researcher affiliated with the Instituto de Investigación Sanitaria Gregorio Marañón, Spain, and is associated with Reproduction Immunology. His supplied Scopus profile records 34 documents, 1,417 citations, and an h-index of 21. His researcher identity is additionally represented by ORCID 0000-0002-9181-2244.[1]

Abstract

Miguel Relloso is a researcher affiliated with the Instituto de Investigación Sanitaria Gregorio Marañón in Spain and associated with the research area of Reproduction Immunology. The supplied bibliometric profile records 34 documents, 1,417 citations, and an h-index of 21. His academic identity is further represented through ORCID identifier 0000-0002-9181-2244 and Scopus Author ID 6602575402.[1]

Keywords

Miguel Relloso; Reproduction Immunology; reproductive immunology; immunology; biomedical research; medical research; research impact; scholarly publications; bibliometrics; Scopus; ORCID; research recognition; Innovative Research Award.[2]

Introduction

Reproduction Immunology examines immunological mechanisms and interactions relevant to reproductive biology and reproductive health. Research in this interdisciplinary area may incorporate cellular, molecular, clinical, and translational approaches. Bibliographic databases can provide structured information for documenting scholarly publications, citation activity, and researcher-associated records within specialized scientific fields.[2]

Research Profile

Miguel Relloso is identified with the Instituto de Investigación Sanitaria Gregorio Marañón, Spain, and the subject area of Reproduction Immunology. His supplied Scopus Author ID is 6602575402, while his ORCID identifier is 0000-0002-9181-2244. These persistent identifiers support the association of scholarly records with an individual researcher and can assist with distinguishing researchers who have similar names.[3]

Research Contributions

The available profile information places Relloso’s research within Reproduction Immunology. His documented institutional affiliation and indexed scholarly record provide identifiable information for describing his research activity. Research affiliation: Instituto de Investigación Sanitaria Gregorio Marañón, Spain. Research area: Reproduction Immunology. Indexed scholarly documents: 34. Indexed citations: 1,417. Reported h-index: 21.[3]

Publications

The supplied information reports 34 Scopus-indexed documents and provides selected publication records associated with Miguel Relloso. These include research concerning antisperm antibodies, neutrophil-mediated sperm elimination, estradiol, CXCL1 signaling, cervical epithelial responses, and reproductive immunology. The individual publications listed in the references provide article-level bibliographic information and DOI identifiers.[4]

Research Impact

Citation count and h-index are bibliometric indicators used to describe aspects of an indexed scholarly record. The supplied information associates Relloso with 1,417 citations and an h-index of 21 across 34 documents. These indicators should therefore be treated as time-dependent measurements rather than comprehensive assessments of research quality.[4]

Award Suitability

The Innovative Research Award profile is presented in connection with the Medical Lab Scientist Awards. The supplied information documents an institutional affiliation, defined research subject area, persistent ORCID identifier, Scopus author profile, and stated bibliometric indicators.[5]

Conclusion

Miguel Relloso’s academic profile is associated with the Instituto de Investigación Sanitaria Gregorio Marañón in Spain and the research area of Reproduction Immunology. The supplied Scopus information records 34 documents, 1,417 citations, and an h-index of 21. His ORCID identifier further provides a persistent researcher reference. [5]

References

  1. Elsevier. (n.d.). Scopus author details: Miguel Relloso, Author ID 6602575402. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=6602575402
  2. ORCID. (n.d.). Miguel Relloso: ORCID record. ORCID.
    https://orcid.org/0000-0002-9181-2244
  3. Medical Lab Scientist Awards. (n.d.). Medical Lab Scientist Awards.
     https://medicallabscientist.com/
  4. Arribas-Poza, P., Veiga-Fernández, A., Gómez-Oro, C., López-Escobar, N., Olivera-Valle, I., Asensio, F., Clemente, M. I., Pérez-Milán, F., & Relloso, M. (2026). Role of antisperm antibodies in neutrophil-mediated sperm elimination by trogocytosis. Andrology. https://doi.org/10.1111/andr.70315
  5. Salinas-Muñoz, L., Campos-Fernández, R., Olivera-Valle, I., Mercader, E., Fernandez-Pacheco, C., Lasarte, S., Pérez-Martín, L., Navarro-González, M. T., Sánchez-Mateos, P., Samaniego, R., & Relloso, M. (2019). Estradiol impairs epithelial CXCL1 gradient in the cervix to delay neutrophil transepithelial migration during insemination. Journal of Reproductive Immunology, 133, 7–14.
    https://doi.org/10.1016/j.jri.2019.02.002